Phase II Study of Ofatumumab as Front-line Treatment in Elderly, Unfit Patients with Chronic Lymphocytic Leukemia (CLL)
The goal of this clinical research study is to learn if ofatumumab can help to control CLL. The safety of this drug will also be studied. Ofatumumab is designed to bind to the surface of the leukemia cells . This may cause the leukemia cells to die.
Treatment Location: N/A
Primary Objective: 1. To evaluate the overall response rate of ofatumumab in the upfront setting in elderly, unfit patients with CLL. Secondary Objective: 1. To determine the overall survival with ofatumumab in upfront setting in elderly, unfit CLL patients. 2. To evaluate the complete response rate and time to progression to therapy of ofatumumab in elderly, unfit patients with CLL. 3. To determine the plasma levels of ofatumumab in elderly, unfit patients. 4. To evaluate predictive capability of miRNAs detection in plasma samples
IRB Review and Approval Date: 12/15/2011
Recruitment Status: Closed
Projected Accrual: N/A